Search Results
Jan 22, 2026, 12:30 ET Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients
More news about: Trevi Therapeutics, Inc.
Jan 08, 2026, 07:30 ET Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough
More news about: Trevi Therapeutics, Inc.
Dec 04, 2025, 07:30 ET Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough
More news about: Trevi Therapeutics, Inc.
Nov 13, 2025, 16:05 ET Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough
More news about: Trevi Therapeutics, Inc.
Nov 06, 2025, 16:05 ET Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough
More news about: Trevi Therapeutics, Inc.
Nov 04, 2025, 07:30 ET Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough
More news about: Trevi Therapeutics, Inc.
Oct 08, 2025, 07:30 ET Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients
More news about: Trevi Therapeutics, Inc.
Sep 18, 2025, 07:30 ET Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough
More news about: Trevi Therapeutics, Inc.